NEW YORK, February 8, 2021 — EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development and scaling of its technology, and expand commercial efforts.

Based in New York City, EVQLV combines the latest advances in machine learning with massive amounts of biological data in order to accelerate the discovery and development of biologics, with a current focus on antibodies. Andrew Satz, CEO of EVQLV said “Our near-term goals are to deepen our relationships with our partners, execute on a dozen lab experiments, engage with innovative and forward-thinking companies, build additional technical innovations and capacity, and continue our rapid growth trajectory.”

“This funding will allow our incredible team to focus our efforts on achieving technical, scientific, and commercial milestones over the coming months” Satz continues. “Our achievements to date are a testament to the determination and agility of our team and the support of our partners. We are incredibly fortunate to be joined by this group of investors, whose skills and experience can aid in our mission of accelerating the speed that healing reaches those in need.”